Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours · corneal abrasion (post‐trauma or post‐surgical)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Proportion of participants with complications at longest time point Up to 2 weeks · corneal abrasion (post‐trauma or post‐surgical)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Changes in mean participant‐reported ocular pain from baseline to 24 hours · corneal abrasion (post‐surgical)
1 finding from 1 review
Changes in mean participant‐reported ocular pain from baseline to 48 hours · corneal abrasion (post‐surgical)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Changes in mean participant‐reported ocular pain from baseline to 72 hours · corneal abrasion (post‐surgical)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours · corneal abrasion (post‐surgical)
It is very uncertain whether topical ophthalmic anesthetic plus NSAID changes proportion of participants without complete resolution of epithelial… compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant probably leads to lower venous thromboembolism compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in major bleeding compared with placebo or no treatment (low certainty).
1 finding from 1 review
Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in deep vein thrombosis compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in need for hospitalisation compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Blood transfusion · Percutaneous nephrolithotomy
Systemic TXA probably leads to lower blood transfusion compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Blood transfusion · Percutaneous nephrolithotomy
Topical TXA probably leads to lower blood transfusion compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Stone‐free rate · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in stone‐free rate compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Thromboembolic events · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in thromboembolic events compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Adverse event · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in adverse event compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Secondary interventions · Percutaneous nephrolithotomy
1 finding from 1 review
Major surgical complications · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in major surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review